Loading...
•
Dec 31, 2023
Verve Therapeutics Q4 2023 Earnings Report
Verve Therapeutics reported financial results and pipeline updates.
Key Takeaways
Verve Therapeutics reported a net loss of $48.4 million for Q4 2023, with cash, cash equivalents, and marketable securities totaling $624.0 million as of December 31, 2023, expected to fund operations into late 2026. The company made progress with its clinical programs, including VERVE-101, VERVE-102, and VERVE-201, and anticipates having three in vivo gene editing programs in the clinic in 2024.
First human proof-of-concept data for in vivo base editing demonstrated in Heart-1 Phase 1b clinical trial of VERVE-101.
Three clinical-stage programs targeting PCSK9 and ANGPTL3 are expected in 2024.
IND clearance received from U.S. FDA for VERVE-101.
Cash, cash equivalents, and marketable securities totaled $624 million, providing a cash runway into late 2026.
Revenue by Segment
Forward Guidance
Verve Therapeutics anticipates several milestones in 2024, including dosing the first patient in the U.S. in the VERVE-101 trial, completing enrollment in the Phase 1b trial of VERVE-101, initiating the Heart-2 Phase 1b trial for VERVE-102, and initiating a Phase 1b trial for VERVE-201.
Positive Outlook
- Dose the first patient in the United States in the VERVE-101 trial.
- Complete enrollment in the ongoing Phase 1b trial of VERVE-101 and provide a data update.
- Initiate the Heart-2 Phase 1b trial for VERVE-102 targeting PCSK9 in the first half of the year.
- Initiate a Phase 1b trial for VERVE-201 targeting ANGPTL3 in the second half of the year.
- Have three in vivo gene editing programs in the clinic in 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...